‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Kyle LaHucik

Associate Editor

Antiva Biosciences has picked up another $53 million to bankroll two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions.

The decade-old South San Francisco biotech will test ABI-2280 in a global Phase II clinical trial in high-grade precancerous cervical lesions — known as cervical intraepithelial neoplasia (CIN 2,3) — and run an exploratory study to see if it can be a treatment for high-risk HPV infection.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence

‘Sleep­ing block­buster’: MPM leads $53M Se­ries E for An­ti­va as biotech seeks sec­ond go at tack­ling HPV

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence